<DOC>
	<DOCNO>NCT00174941</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety febuxostat , daily ( QD ) , maintain serum urate level within clinically acceptable level subject gout .</brief_summary>
	<brief_title>Long-Term Safety Febuxostat Subjects With Gout .</brief_title>
	<detailed_description>Uric acid end product purine degradation human . Hyperuricemia , urate concentration serum exceed limit urate solubility ( approximately 7.0 milligram per deciliter [ mg/dL ] ) , common biochemical abnormality . Aberrations multiple mechanism involve production and/or excretion uric acid may increase serum urate concentration , persistent hyperuricemia marker extracellular fluid monosodium urate supersaturation . As , hyperuricemia necessary ( often sufficient ) risk factor monosodium urate crystal deposition tissue fundamental pathophysiological process underlie clinical manifestation gout , chronic disease characterize urate crystal formation deposition joint bone . Gout may progress episodic attack acute inflammatory arthritis disable chronic disorder characterize deform arthropathy ; destructive deposit urate crystal ( tophus ) bone , joint , organ ; structural functional renal impairment due interstitial urate crystal deposition ; urinary tract stone compose entirely part uric acid crystal . Management gout require chronic treatment aim lower serum urate subsaturating range ( usually &lt; 6.0 mg/dL ) crystal formation deposition prevent reverse . Febuxostat ( TMX-67 ) non-purine selective xanthine oxidase inhibitor develop orally administer agent management hyperuricemia patient gout . Subjects want participate study successfully complete study TMX-00-004 ( NCT00174967 ) . All participant initially receive 80 mg dose . Dose titration occur order obtain maintain clinically acceptable serum urate level .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Hyperuricemia ( serum uric acid â‰¥8.0 mg/dL upon enter parent study TMX00004 ) . Must meet American College Rheumatology criterion gout . Must adequate renal function ( serum creatinine &lt; 1.5 mg/dL ) . Must complete four week doubleblind dose Study TMX00004 . Must experience serious study drugrelated Adverse Events Study TMX 00004 . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . History xanthinuria Alcohol consumption &gt; 14/week Has History significant concomitant illness Has active liver disease . Has body mass index great 50 kg/m2 Any significant medical condition would interfere treatment , safety compliance protocol , define investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Uric acid</keyword>
	<keyword>xanthine oxidase</keyword>
	<keyword>tophus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>